Profile of total IgG, IgG1, IgG2, IgG3 and IgG4 levels in sera of patients with paracoccidioidomycosis: treatment follow-up using Mexo and rPb27 as antigens in an ELISA

• Main Authors: Lílian da Silva Santos, Viviane Cristina Fernandes, Samuel Gonçalves da Cruz, Weverton César Siqueira, Alfredo Miranda Goes, Ênio Roberto Pietra Pedroso
• Format: Article
• Language: English
• Published: Instituto Oswaldo Cruz, Ministério da Saúde 2012-02-01
• Series: Memórias do Instituto Oswaldo Cruz.
• Subjects: treatment follow-up; ELISA; Mexo antigen; rPb27 antigen; paracoccidioidomycosis; IgG subclasses
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000100001&lng=en&tlng=en

The levels of total of IgG, IgG1, IgG2, IgG3 and IgG4 were evaluated in 54 patients with chronic paracoccidioidomycosis (PCM) before, during and after treatment using an enzyme-linked immunosorbent assay with Mexo and recombinant Pb27 (rPb27) as the antigens. Mexo was effective in distinguishing PCM patients from individuals in the negative control group (NC) based on total IgG and rPb27 performed worse than Mexo when these two groups were compared. IgG1, IgG2, IgG3 and IgG4 could not be used to clearly distinguish PCM patients from those in the NC group using either antigen. There was no clear relationship between antibody levels and the period of treatment. The majority of patients presented with decreased antibody levels during treatment, with no statistically significant differences among the different periods of treatment. Only IgG4 presented a negative correlation between its levels and clinical improvement during treatment. In total, 65% of untreated PCM patients showed reactivity against IgG4 when the Mexo antigen was used and this reactivity decreased over the course of treatment. There was a tendency towards decreasing antibody levels during treatment, but these antibody levels did not necessarily clear after the treatment was stopped. Mexo was useful for PCM diagnosis using total IgG; however, more studies are necessary before this antigen can be used in measuring the levels of total IgG and its subclasses for monitoring patients during treatment.